66.09 -0.24 (-0.36%)
After hours: 7:12PM EDT
|Bid||66.20 x 2200|
|Ask||66.50 x 1300|
|Day's Range||65.77 - 68.99|
|52 Week Range||33.86 - 71.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 23, 2018 - Jul 27, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.10|
As concerns over trade wars escalate, investors may find refuge in small-cap stocks, which have been handily beating the broader market this year. Lower exposure to trade risk along with beneficial tax policy exposures, relative strength in U.S. economic growth, and potential merger activity, make small caps like GrubHub Inc. ( GRUB), Exact Sciences Corp. ( EXAS) and Aspen Technology Inc. ( AZPN), especially attractive in the current environment, according to CNBC.
MADISON, Wis., June 19, 2018 /PRNewswire/ -- The national colon cancer screening movement led by golfer Jerry Kelly will be front and center when the PGA TOUR Champions comes to University Ridge Golf Course June 22-24, 2018 for the American Family Insurance Championship (AmFam Championship). Today, the American Family Insurance Championship and Exact Sciences announced an expanded partnership that makes the Madison-based company and its noninvasive colon cancer screening test, Cologuard, one of the leading partners of the 2018 event.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 18) Aptose Biosciences Inc (NASDAQ: APTO ) Arrowhead Pharmaceuticals ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on June 7) Baxter International Inc (NYSE: BAX ) Bio-Rad Laboratories, ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
MADISON, Wis., June 8, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 1.0% Convertible Senior Notes due 2025 (the "Notes") and upsized the offering from $150 million to $190 million aggregate principal amount, providing for total gross proceeds of $202.4 million, excluding accrued interest. The initial public offering price for the Notes will be 106.5% of face value plus accrued interest from January 17, 2018. The Notes issuance is a reopening of, and will be fully fungible and form a single series with, the $690 million aggregate principal amount of the Company's 1.0% Convertible Senior Notes Due 2025 issued by the Company on January 17, 2018 and will have the same CUSIP number. The Company has granted the underwriters a 30-day option to purchase up to an additional $28.5 million aggregate principal amount of the Notes at the public offering price, less the underwriting discount, plus accrued interest.
MADISON, Wis., June 7, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) today announced an underwritten public offering of $150 million aggregate principal amount of its 1.0% convertible senior notes due 2025 (the "Notes") in a registered public offering. The Company also plans to grant to the underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes at the public offering price, less the underwriting discount, plus accrued interest. The Notes issuance is a reopening of, and will be part of the same series as, the $690 million aggregate principal amount of 1.0% Convertible Senior Notes due 2025 issued by the Company on January 17, 2018.
Exact Sciences broke out to a record high Wednesday after the biotech showed its newest blood test could detect curable liver cancer in 91% of patients studied.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...
Data Presented at Digestive Disease Week Show Panel of Six Biomarkers is 95 Percent Sensitive for Most Common Type of Liver Cancer WASHINGTON , June 5, 2018 /PRNewswire/ -- Researchers at Exact Sciences ...
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
Cologuard is currently available to individuals age 50 and older who are at average risk for colorectal cancer.
MADISON, Wis., June 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences during June and invited investors to participate by webcast. The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
MADISON, Wis., May 30, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) strongly supports the American Cancer Society's (ACS) update to its colorectal cancer screening guidelines announced today. The new guidelines recommend colorectal cancer screening begin at age 45 for people at average risk of the disease. With more than 20 million Americans age 45-49, Exact Sciences affirmed its commitment to seek U.S. Food and Drug Administration (FDA) approval for making Cologuard, its noninvasive colorectal cancer screening test, available to those in this population who are at average risk for colorectal cancer.
Shares jump after the American Cancer Society tweaks its recommended guidelines for cancer screening. Here's what investors need to know.
The American Cancer Society on Wednesday recommended that people at average risk of colorectal cancer start regular screening at the age of 45 rather than at 50, at a time when studies show a rise in cases of the disease among younger individuals. The new ACS guideline https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html also recommends people, who are in good health and with a life expectancy of more than 10 years, should continue regular colorectal cancer screening through the age of 75. The guideline suggests screening either through a high sensitivity stool-based test or visual examination such as colonoscopy that snakes a tiny camera through the rectum to view the colon to search for abnormal tissue growth.
Exact Sciences Corp. , maker of a colon cancer test, had shares surge 11% in extremely heavy Wednesday trade after the American Cancer Society recommended screening for colon cancers starting five years earlier, at age 45.
After reading Exact Sciences Corporation’s (NASDAQ:EXAS) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...
Biotech stocks are breaking out, with the SPDR S&P Biotech ETF ( XBI) gearing up for what could be a significant rise higher. Since that time the group has turned higher, and now technical analysis suggests more gains may lie ahead for the sector.
NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Boardwalk ...
The new partnership includes the organizations collaborating on national campaigns and donations made to the foundation from the medical device company.
MILWAUKEE and MADISON, Wis., May 3, 2018 /PRNewswire/ -- Colon cancer cut short the life of legendary football coach Vince Lombardi at the age of 57 and, nearly 50 years later, remains the number two cancer killer in the United States. Now, the foundation bearing his name and one of the country's premier cancer diagnostics companies are teaming up to fight back. Today, the Vince Lombardi Cancer Foundation (VLCF) announced a new, multi-year partnership with Madison, Wis.-based Exact Sciences that will work to increase awareness of colon cancer, stress the importance of screening and prevention, and raise funds for cancer research.